These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 22927417)

  • 1. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
    Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 3. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs.
    Li M; Kao E; Malone D; Gao X; Wang JYJ; David M
    Nat Struct Mol Biol; 2018 Nov; 25(11):1047-1058. PubMed ID: 30374083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
    Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
    Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
    Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents).
    Luan J; Gao X; Hu F; Zhang Y; Gou X
    J Drug Target; 2020 Jan; 28(1):33-40. PubMed ID: 31092045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.
    Murai J; Zhang H; Pongor L; Tang SW; Jo U; Moribe F; Ma Y; Tomita M; Pommier Y
    Cell Rep; 2020 Mar; 30(12):4137-4151.e6. PubMed ID: 32209474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
    Zhang B; Ramkumar K; Cardnell RJ; Gay CM; Stewart CA; Wang WL; Fujimoto J; Wistuba II; Byers LA
    Br J Cancer; 2021 Nov; 125(10):1333-1340. PubMed ID: 34294893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.
    Ballestrero A; Bedognetti D; Ferraioli D; Franceschelli P; Labidi-Galy SI; Leo E; Murai J; Pommier Y; Tsantoulis P; Vellone VG; Zoppoli G
    J Transl Med; 2017 Oct; 15(1):199. PubMed ID: 28969705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    Onji H; Murai J
    Cancer Sci; 2022 Sep; 113(9):2943-2951. PubMed ID: 35766436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    Willis SE; Winkler C; Roudier MP; Baird T; Marco-Casanova P; Jones EV; Rowe P; Rodriguez-Canales J; Angell HK; Ng FSL; Waring PM; Hodgson D; Ledermann JA; Weberpals JI; Dean E; Harrington EA; Barrett JC; Pierce AJ; Leo E; Jones GN
    Br J Cancer; 2021 Dec; 125(12):1666-1676. PubMed ID: 34663950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
    Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
    Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
    Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
    Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
    Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
    Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response.
    Malone D; Lardelli RM; Li M; David M
    J Biol Chem; 2019 Oct; 294(40):14674-14685. PubMed ID: 31395656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.